What fans the fire: Insights into mechanisms of leptin in metabolic syndrome- associated heart diseases

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 652-658

  Dong, Maolong ^a,b   Rena, Jun ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular disease; Leptin; Leptin resistance; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CARDIOVASCULAR AGENT; GLYCOPROTEIN GP 130; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; LEUKEMIA INHIBITORY FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HEART DISEASE; HEART FUNCTION; HEART RATE; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR SYSTEM; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HEART DISEASES; HUMANS; LEPTIN; METABOLIC SYNDROME X; MODELS, CARDIOVASCULAR; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION;

EID: 84894101773     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282004140213160930     Document Type: Review

References (143)

1. Zoccali C, Seck SM, Mallamaci F. Obesity and the epidemiology and prevention of kidney disease: waist circumference versus body mass index. Am J Kidney Dis 2011; 58: 157-9.
2. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: 143-52.
3. Lloyd LJ, Langley-Evans SC, McMullen S. Childhood obesity and risk of the adult metabolic syndrome: a systematic review. Int J Obe 2012; 36: 1-11.
4. Jindal A, Brietzke S, Sowers JR. Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. Cardiorenal Med 2012; 2: 314-27.
5. Guinhouya BC, Samouda H, Zitouni D, et al. Evidence of the influence of physical activity on the metabolic syndrome and/or on insulin resistance in pediatric populations: a systematic review. International journal of pediatric obesity: IJPO: an official journal of the International Association for the Study of Obesity 2011; 6: 361-88.
6. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348: 1085-95.
7. Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment-A position paper of the The Obesity Society and the American Society of Hypertension. Obesity 2012.
8. Barton M. Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Arch 2010; 460: 825-37.
9. Sweeney G. Cardiovascular effects of leptin. Nat Rev Cardiol 2010; 7: 22-9.
10. Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271-6.
11. Achike FI, To NH, Wang H, et al. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol 2011; 38: 1-10.
12. Sowers JR. Obesity and cardiovascular disease. Clin Chem 1998; 44: 1821-5.
13. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002; 1585: 202-12.
14. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
15. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008; 117: 3238-49.
16. Ren J, Ma H. Impaired cardiac function in leptin-deficient mice. Current hypertension reports 2008; 10: 448-53.
17. Dong F, Ren J. Fitness or fatness-the debate continues for the role of leptin in obesity-associated heart dysfunction. Current diabetes reviews 2007; 3: 159-64.
18. Ren J. Lessons from the leptin paradox in cardiac regulation-too much versus too little. The J Physiol 2005; 565: 347.
19. Caro JF, Sinha MK, Kolaczynski JW, et al. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-62.
20. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
21. Leibel RL, Chung WK, Chua SC, Jr. The molecular genetics of rodent single gene obesities. J Biol Chem 1997; 272: 31937-40.
22. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37.
23. Sweeney G. Leptin signalling. Cell Signal 2002; 14: 655-63.
24. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-56.
25. Mancuso P, Myers MG, Jr., Goel D, et al. Ablation of leptin receptor-mediated ERK activation impairs host defense against Gram-negative pneumonia. J Immunol 2012; 189: 867-75.
26. Lopez-Bergami P. The role of mitogen-and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011; 24: 902-21.
27. Bouloumie A, Marumo T, Lafontan M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 1231-8.
28. Anderson CM, Ren J. Leptin, leptin resistance and endothelial dysfunction in pre-eclampsia. Cell Mol Biol (Noisy-le-grand) 2002; 48 Online Pub: OL323-9.
29. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-9.
30. Enriori PJ, Sinnayah P, Simonds SE, et al. Leptin action in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of systemic leptin resistance. J Neurosci 2011; 31: 12189-97.
31. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev 2002; 60: S1-14; discussion S68-84, 5-7.
32. do Carmo JM, da Silva AA, Cai Z, et al. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension 2011; 57: 918-26.
33. Bjorbaek C, Uotani S, da Silva B, et al. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-95.
34. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesityassociated cardiovascular and renal disease. Am J Med Sci 2002; 324: 127-37.
35. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379-88.
36. Haynes WG, Morgan DA, Walsh SA, et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-8.
37. Chen L, Philippe J, Unger RH. Glucagon responses of isolated alpha cells to glucose, insulin, somatostatin, and leptin. Endocr Pract 2011; 17: 819-25.
38. Cicero AF, Magni P, More M, et al. Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the brisighella heart study. Int J Endocrinol 2011; 2011: 724816.
39. Hamed EA, Zakary MM, Ahmed NS, et al. Circulating leptin and insulin in obese patients with and without type 2 diabetes mellitus: relation to ghrelin and oxidative stress. Diabetes Res Clin Pract 2011; 94: 434-41.
40. Hilzendeger AM, Goncalves AC, Plehm R, et al. Autonomic dysregulation in ob/ob mice is improved by inhibition of angiotensin-converting enzyme. J Mol Med (Berl) 2010; 88: 383-90.
41. Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-alpha and GPER signalling. Mol Cell Endocrinol 2012.
42. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesityassociated abnormalities? Acta physiologica 2012; 205: 209-23.
43. Kellerer M, Koch M, Metzinger E, et al. Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways. Diabetologia 1997; 40: 1358-62.
44. Kolter T, Uphues I, Eckel J. Molecular analysis of insulin resistance in isolated ventricular cardiomyocytes of obese Zucker rats. Am J Physiol 1997; 273: E59-67.
45. Zhao AZ, Bornfeldt KE, Beavo JA. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 1998; 102: 869-73.
46. Harvey J, McKay NG, Walker KS, et al. Essential role of phosphoinositide 3-kinase in leptin-induced K(ATP) channel activation in the rat CRI-G1 insulinoma cell line. J Biol Chem 2000; 275: 4660-9.
47. Northcott CA, Poy MN, Najjar SM, et al. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res 2002; 91: 360-9.
48. Wold LE, Relling DP, Duan J, et al. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 2002; 39: 69-74.
49. German JP, Thaler JP, Wisse BE, et al. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology 2011; 152: 394-404.
50. Mancuso P, Gottschalk A, Phare SM, et al. Leptin-deficient mice exhibit impaired host defense in Gram-negative pneumonia. Journal of immunology 2002; 168: 4018-24.
51. Delfini E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 2007; 56: 30-6.
52. Wrann CD, Laue T, Hubner L, et al. Short-term and long-term leptin exposure differentially affect human natural killer cell immune functions. Am J Physiol Endocrinol Metab 2012; 302: E108-16.
53. Paulson DJ, Tahiliani AG. Cardiovascular abnormalities associated with human and rodent obesity. Life Sci 1992; 51: 1557-69.
54. Laitinen J. Obesity is a health problem. Int J Circumpolar Health 1998; 57: 104-8.
55. Chakko S, Mayor M, Allison MD, et al. Abnormal left ventricular diastolic filling in eccentric left ventricular hypertrophy of obesity. Am J Cardiol 1991; 68: 95-8.
56. Carroll JF. Post-beta-receptor defect in isolated hearts of obesehypertensive rabbits. Int J Obes Relat Metab Disord 1999; 23: 863-6.
57. Ren J, Sowers JR, Walsh MF, et al. Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. American journal of physiology Heart and circulatory physiology 2000; 279: H1708-14.
58. Nickola MW, Wold LE, Colligan PB, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 2000; 36: 501-5.
59. Carroll JF, Summers RL, Dzielak DJ, et al. Diastolic compliance is reduced in obese rabbits. Hypertension 1999; 33: 811-5.
60. Schmieder RE, Messerli FH. Obesity hypertension. Med Clin North Am 1987; 71: 991-1001.
61. de la Maza MP, Estevez A, Bunout D, et al. Ventricular mass in hypertensive and normotensive obese subjects. Int J Obes Relat Metab Disord 1994; 18: 193-7.
62. Carroll JF, Jones AE, Hester RL, et al. Reduced cardiac contractile responsiveness to isoproterenol in obese rabbits. Hypertension 1997; 30: 1376-81.
63. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997; 23 Suppl 3: 16-24.
64. Hintz KK, Aberle NS, Ren J. Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord 2003; 27: 1196-203.
65. Korda M, Kubant R, Patton S, et al. Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol 2008; 295: H1514-21.
66. Bodary PF. Links between adipose tissue and thrombosis in the mouse. Arterioscler Thromb Vasc Biol 2007; 27: 2284-91.
67. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-7.
68. Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-100.
69. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90: 711-8.
70. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002; 51: 168-73.
71. Procopio C, Andreozzi F, Laratta E, et al. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5'-monophosphate-activated protein kinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology 2009; 150: 3584-93.
72. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease? Circulation 2002; 106: 1919-24.
73. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-6.
74. Parhami F, Tintut Y, Ballard A, et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 2001; 88: 954-60.
75. Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40.
76. Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 426-9.
77. Elbatarny HS, Maurice DH. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am J Physiol Endocrinol Metab 2005; 289: E695-702.
78. De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002; 25: 899-904.
79. Darvall KAL, Sam RC, Silverman SH, et al. Obesity and thrombosis. European Journal of Vascular and Endovascular Surgery 2007; 33: 223-33.
80. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-8.
81. Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 2004; 181: 1-10.
82. Narkiewicz K, Somers VK, Mos L, et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertens 1999; 17: 245-9.
83. Rajapurohitam V, Javadov S, Purdham DM, et al. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J Mol Cell Cardiol 2006; 41: 265-74.
84. Majumdar P, Chen S, George B, et al. Leptin and endothelin-1 mediated increased extracellular matrix protein production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes Metab Res Rev 2009; 25: 452-63.
85. Madani S, De Girolamo S, Munoz DM, et al. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovascular research 2006; 69: 716-25.
86. Schram K, Wong MM, Palanivel R, et al. Increased expression and cell surface localization of MT1-MMP plays a role in stimulation of MMP-2 activity by leptin in neonatal rat cardiac myofibroblasts. J Mol Cell Cardiol 2008; 44: 874-81.
87. Kshatriya S, Liu K, Salah A, et al. Obesity hypertension: the regulatory role of leptin. Int J Hypertens 2011; 2011: 270624.
88. Satoh N, Ogawa Y, Katsuura G, et al. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 1999; 48: 1787-93.
89. Shankar A, Xiao J. Positive relationship between plasma leptin level and hypertension. Hypertension 2010; 56: 623-8.
90. Asferg C, Mogelvang R, Flyvbjerg A, et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens 2010; 23: 327-33.
91. Shirasaka T, Takasaki M, Kannan H. Cardiovascular effects of leptin and orexins. Am J Physiol Regul Integr Comp Physiol 2003; 284: R639-51.
92. Kimura K, Tsuda K, Baba A, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. Biochem Biophys Res Commun 2000; 273: 745-9.
93. Nakagawa K, Higashi Y, Sasaki S, et al. Leptin causes vasodilation in humans. Hypertens Res 2002; 25: 161-5.
94. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105: 1243-52.
95. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31: 409-14.
96. Haynes WG. Interaction between leptin and sympathetic nervous system in hypertension. Current Hyperten Rep 2000; 2: 311-8.
97. Mark AL, Correia ML, Rahmouni K, et al. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20: 1245-50.
98. Mark AL, Shaffer RA, Correia ML, et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999; 17: 1949-53.
99. Correia ML, Haynes WG, Rahmouni K, et al. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51: 439-42.
100. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
101. Konstantinidis D, Paletas K, Koliakos G, et al. Signaling components involved in leptin-induced amplification of the atherosclerosis-related properties of human monocytes. J Vasc Res 2009; 46: 199-208.
102. Hasty AH, Shimano H, Osuga J, et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 2001; 276: 37402-8.
103. Matsui T, Tao J, del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104: 330-5.
104. Zhang Y, Xia Z, La Cour KH, et al. Activation of Akt rescues endoplasmic reticulum stress-impaired murine cardiac contractile function via glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeation pore opening. Antioxidants & redox signaling 2011; 15: 2407-24.
105. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-61.
106. Considine RV, Caro JF. Leptin in humans: current progress and future directions. Clin Chem 1996; 42: 843-4.
107. Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab 1996; 81: 3424-7.
108. Agata J, Masuda A, Takada M, et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997; 10: 1171-4.
109. Haynes WG, Morgan DA, Walsh SA, et al. Cardiovascular consequences of obesity: role of leptin. Clin Exp Pharmacol Physiol 1998; 25: 65-9.
110. Relling DP, Hintz KK, Ren J. Acute exposure of ceramide enhances cardiac contractile function in isolated ventricular myocytes. Br J Pharmacol 2003; 140: 1163-8.
111. Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996; 45: 988-91.
112. Paolisso G, Tagliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin-resistant men. Hypertension 1999; 34: 1047-52.
113. Kelly RA, Smith TW. Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol 1996; 77: 2C-7C.
114. Ren J, Natavio M, Jefferson L, et al. Loss of cardiac contractile response to tetrahydropapaveroline with advanced age and hypertension. Cell Mol Biol (Noisy-le-grand) 2001; 47 Online Pub: OL15-22.
115. Van Gaal LF, Zhang A, Steijaert MM, et al. Human obesity: from lipid abnormalities to lipid oxidation. Int J Obes Relat Metab Disord 1995; 19 Suppl 3: S21-6.
116. Vincent HK, Powers SK, Stewart DJ, et al. Obesity is associated with increased myocardial oxidative stress. Int J Obes Relat Metab Disord 1999; 23: 67-74.
117. Cleland JG, Clark AL. Leptin and cardiac cachexia: marker or mediator? Eur Heart J 1998; 19: 1421-2.
118. Bottner A, Eisenhofer G, Torpy DJ, et al. Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. Metabolism 1999; 48: 543-5.
119. Balasubramaniam A, Grupp I, Matlib MA, et al. Comparison of the effects of neuropeptide Y (NPY) and 4-norleucine-NPY on isolated perfused rat hearts; effects of NPY on atrial and ventricular strips of rat heart and on rabbit heart mitochondria. Regul Pept 1988; 21: 289-99.
120. Ganguly PK, Sherwood GR. Noradrenaline turnover and metabolism in myocardium following aortic constriction in rats. Cardiovasc Res 1991; 25: 579-85.
121. Millar BC, Piper HM, McDermott BJ. The antiadrenergic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn Schmiedebergs Arch Pharmacol 1988; 338: 426-9.
122. Panchal SK, Poudyal H, Iyer A, et al. High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 2011; 57: 611-24.
123. Li WC, Hsiao KY, Chen IC, et al. Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults. Cardiovasc Diabetol 2011; 10: 36.
124. Kajikawa Y, Ikeda M, Takemoto S, et al. Association of circulating levels of leptin and adiponectin with metabolic syndrome and coronary heart disease in patients with various coronary risk factors. Int Heart J 2011; 52: 17-22.
125. Hecker PA, O'Shea KM, Galvao TF, et al. Role of adiponectin in the development of high fat diet-induced metabolic abnormalities in mice. Horm Metab Res 2011; 43: 100-5.
126. Forli L, Bollerslev J, Simonsen S, et al. Disturbed energy metabolism after lung and heart transplantation. Clin Transplant 2011; 25: E136-43.
127. Pyzik M. [Leptin level in ischemic stroke]. Pol Merkur Lekarski 2010; 28: 371-5.
128. Miesel A, Muller H, Thermann M, et al. Overfeeding-induced obesity in spontaneously hypertensive rats: an animal model of the human metabolic syndrome. Ann Nutr Metab 2010; 56: 127-42.
129. Ezenwaka CE, Nwagbara E, Seales D, et al. Insulin resistance, leptin and monocyte chemotactic protein-1 levels in diabetic and non-diabetic Afro-Caribbean subjects. Arch Physiol Biochem 2009; 115: 22-7.
130. Van den Bergh A, Vanderper A, Vangheluwe P, et al. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovascular research 2008; 77: 371-9.
131. Galletti F, Barbato A, Versiero M, et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. J Hypertens 2007; 25: 1671-7.
132. Franks PW, Brage S, Luan J, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-84.
133. Piatti P, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-81.
134. Al-Daghri N, Al-Rubean K, Bartlett WA, et al. Serum leptin is elevated in Saudi Arabian patients with metabolic syndrome and coronary artery disease. Diabet Med 2003; 20: 832-7.
135. Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5: 33-40.
136. Makris TK, Stavroulakis GA, Krespi PG, et al. Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension. Am Heart J 1999; 138: 922-5.
137. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-6.
138. Langenberg C, Bergstrom J, Scheidt-Nave C, et al. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006; 29: 1363-9.
139. Unger RH. Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005; 45: 1031-4.
140. McGaffin KR, Zou B, McTiernan CF, et al. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovas Res 2009; 83: 313-24.
141. McGaffin KR, Moravec CS, McTiernan CF. Leptin signaling in the failing and mechanically unloaded human heart. Circulation Heart failure 2009; 2: 676-83.
142. Smith CC, Dixon RA, Wynne AM, et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010; 299: H1265-70.
143. McGaffin KR, Witham WG, Yester KA, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res 2011; 89: 60-71